National Center for Advancing Translational Sciences in New Jersey
National Center for Advancing Translational Sciences (93.350) awarded $31.6 million to recipients in New Jersey in 13 grants from fiscal 2021 to 2025, 1.0% of the program's national total. Rutgers the State University of New Jersey received the most, $30.1 million.
- Awarded in New Jersey$31.6 million
- Awards13
- Share of the program1.0%
- Rank among states25th of 41
- National total$3.1 billion
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 4 | $6.6 million |
| FY 2022 | 7 | $5.9 million |
| FY 2023 | 4 | $4.8 million |
| FY 2024 | 6 | $7.7 million |
| FY 2025 | 5 | $6.6 million |
Recipients in New Jersey
| Recipient | Type | Awards | Amount |
|---|---|---|---|
| Rutgers the State University of New Jersey | Colleges and universities | 8 | $30.1 million |
| Tetmedical, Inc. | Small businesses | 1 | $324,962 |
| Inaedis, Inc | Small businesses | 1 | $312,634 |
| Analytical Diagnostic Solutions Inc | Small businesses | 1 | $305,352 |
| Nemagen Discoveries Inc | Small businesses | 1 | $300,480 |
| Optimeos Life Sciences, Inc. | Small businesses | 1 | $287,726 |
Open opportunities under this program
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
- Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25 - Clinical Trial Not Allowed)
- Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
- Clinical and Translational Science Award (UM1 Clinical Trial Optional)
- Limited Competition: Mentored Research Career Development Program Award in Clinical and Translational Science Awards (CTSA) Program (K12 Clinical Trial Optional)
See all 34 on the program page
Questions people ask
How much National Center for Advancing Translational Sciences money goes to New Jersey?
$31.6 million from fiscal 2021 to 2025, across 13 awards. New Jersey ranks 25th of 41 states and territories for this program.
Who receives National Center for Advancing Translational Sciences money in New Jersey?
The largest recipient is Rutgers the State University of New Jersey, with $30.1 million in 8 awards. Next are Tetmedical, Inc. and Inaedis, Inc.
Can organizations in New Jersey apply now?
Yes, 34 opportunities under this program are open or forecast on Grants.gov. Federal grants are national, so eligibility depends on the notice, not the state.
National Center for Advancing Translational Sciences in other states
Other large programs in New Jersey
- Grants to States for Medicaid
- Highway Planning and Construction
- Education Stabilization Fund
- Federal Transit Formula Grants
- Disaster Grants - Public Assistance (Presidentially Declared Disasters)
- National School Lunch Program
- Children's Health Insurance Program
- Special Education Grants to States
- 1332 State Innovation Waivers
- Title I Grants to Local Educational Agencies